EGETIS THERAPEUTICS

WE CARE

FOR THE RARE

Webcast - Quarter 2 2026 Report

August 21, 2026

Egetis Therapeutics

For analysts and investors

Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Egetis Therapeutics AB (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information"). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is not intended for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any other jurisdiction where such distribution would be unlawful. This presentation is not a prospectus or similar document and it has not been approved, registered or reviewed by the Swedish Financial Supervisory Authority nor any governmental authority or stock exchange in any jurisdiction.

The Information has been prepared by the Company and is intended to present background information on the Company, its business and the industry in which it operates. The Information contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation. The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained therein shall form the basis of or be relied on in connection with any investment activity. The Company shall not have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of the Information or otherwise arising in connection with this presentation.

By accessing this Information, you represent that such access does not violate any registration requirements or other legal restrictions in the jurisdiction in which you reside or conduct business. It is especially noted that the Information may not be accessed by persons within the United States or "U.S. Persons" (as defined in Regulation S under the Securities Act of 1933, as amended (the "Securities Act") unless they are qualified institutional buyers "QIBs" as defined in Rule 144A under the Securities Act. By accessing the Information, you represent that you are (i): a non-U.S. person that is outside the United States or (ii) a QIB. Further, the Information may not be accessed by persons within the United Kingdom unless they are persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "Order"), a "qualified investors" falling within Article 2(e) of Regulation (EU) 2017/1129 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA"), or high net worth entities falling within Article 49(2)(a) to (d) of the Order (each a "Relevant Person"). By accessing the Information, you represent that you are: (i) outside the United Kingdom or (ii) a Relevant Person.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future. As a result, you are cautioned not to place undue reliance on such forward-looking statements.

No representation, warranty or undertaking, express or implied, is made by or on behalf of the Company as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaim any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Agenda for today

Business update	**Nicklas Westerholm, CEO**
Launch preparations in U.S.	Anny Bedard, President, Egetis North America
Commercialization update in EU and other international markets	Henrik Krook, VP Commercial Operations
Financial update	Yilmaz Mahshid, CFO
Looking ahead	Nicklas Westerholm, CEO

Business update

FDA's review of Emcitate® NDA progressing according to plan towards September 28, 2026, PDUFA action date

- Emcitate® launch in the U.S. planned for Q4 2026, subject to approval
- Egetis granted MCT8 deficiency composition patent in the U.S.
- Q2 revenue MSEK 17.4, +23% (CER) vs Q2 2025 and +30% vs Q1 2026
- The Emcitate price negotiations within the German reimbursement process (AMNOG) concluded in Q2 2026 and applied from August
- Egetis successfully carried out an oversubscribed directed share issue amounting to SEK 350 million / USD 38 million (gross)
- Tiago Nunes appointed Chief Medical Officer

Launch preparations in US and commercialization in EU

Q2-2026

The Team is Built and Launch Infrastructure is Being Activated

Experienced Team Ready for Launch

- Core commercial team hiring completed
- Medical and field teams trained and active in the field
- Experienced rare-disease launchers executing a detailed, cross-functional plan

Patient support program

Patient support capabilities and operating model established

Market access

Payer strategy, value communication, and account coverage in place

Distribution & supply

Specialty distribution network and supply capabilities being activated

Medical education

Scientific engagement expanding across diagnosing and treating specialists

Patient finding

Systems operational to support patient identification and launch management

Advocacy & awareness

Caregiver and advocacy partnerships informing launch execution

Continuity of Care for EAP Patients is Our Top Priority

Patient-level transition planning

Confirm the pathway and treating physician for each EAP patient

Enrollment & prescriber readiness

Enrollment/Prescription processes and prescriber/caregiver education prepared ahead of approval

Coverage and continuity safeguards

Coordinate payer engagement, affordability support, and bridge mechanisms to ensure uninterrupted patient access during treatment initiation

Activation & monitoring

Track each transition across the physician, caregiver, specialty pharmacy, patient services, and payer

Tiratricol EAP continuity of care — ensuring uninterrupted treatment at approval

A coordinated transition from expanded access to commercial supply is intended to minimize treatment disruption and support the earliest commercial uptake.

In parallel, we will engage known patients not yet on therapy and continue expanding diagnosis and patient identification.

~60 patients across 17 sites in EAP today — growing month over month

EAP: Expanded Access Program

Europe & International

Q2 revenue MSEK 17.4, +23% (CER) vs Q2 2025 and +30% vs Q1 2026; momentum building on German reimbursement conclusion and broader geographic reach

Germany

- Price negotiations with GKV-Spitzenverband concluded in Q2 2026
- Continued disease awareness, physician engagement and congress presence with pediatric endocrinologists, pediatric neurologists and other specialist physicians

Progressing toward reimbursed pathways in additional countries

- National pricing and reimbursement dossier submitted in Spain
- Italy and France: value dossiers to be strengthened with Emcitate survival data
- Rest of Europe: moving towards funded access routes in more countries

Partnerships driving named patient access in more geographies

- Er-Kim (Turkey, Central, Eastern & Southeastern Europe) and taiba rare (Gulf region) initiating funded treatment
- New agreement with Orspec Pharma for Australia and New Zealand
- Ongoing dialogue with potential partners in additional geographies



Financials

Q2-2026

Financial Overview – Second Quarter

- Total revenue
  - Q2-2026 of 17.4 MSEK vs. 14.5 MSEK for Q2-2025, +23% YoY CER.
- Cost of goods sold impacted by intangible R&D depreciation
  - During Q2-2026 R&D depreciation of 10.1 MSEK is included in COGS
  - Excluding the depreciation Gross profit would have been 13.7 MSEK in the second quarter 2026, adj. gross margin 79%.
- Results after tax in Q2-2026 amounted to -108.9 MSEK vs. -77.6 MSEK for Q2-2025
  - The increased YoY costs are primarily attributed to the US NDA-process and US commercial build-up and pre-launch activities.
  - Opex includes -5.6 MSEK ESOP related non-cash bookings due to the share price appreciation in the quarter, vs. 6.9 MSEK positive booking in Q2-2025. Leading to a YoY delta of 12.5 MSEK
- Cash flow from operating activities in Q2-2026 amounted to -93.9 MSEK vs. -59.0 for Q2-2025
  - April 21, Egetis Therapeutics successfully carried out an oversubscribed directed share issue amounting to 350 MSEK
  - The issue was priced at 5.25 SEK/share, corresponding to 0% discount to market close
  - The cash position per end of June 2026 was 378.4 MSEK vs. 202.6 MSEK per end of June 2025.

MSEK	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Revenue	17.4	14.5	30.7	27.1	62.4
Gross profit	3.6	1.5	3.3	4.7	12.4
Operating result	-108.3	-78.5	-202.2	-143.1	-339.9
Results after tax	-108.9	-77.6	-203.4	-140.5	-342.5
Cash flow from operations	-93.9	-59.0	-158.2	-125.1	-267
Cash position	378.4	202.6	378.4	202.6	215.8

Looking ahead

Emcitate® (tiratricol) U.S. Launch in 2026 and indication expansion opportunity

Upcoming key milestones

- PDUFA date September 28
- Priority Review Voucher (upon approval)
- Expected launch of Emcitate® (tiratricol) in the U.S. (Q4)
- Finalize the development plan for Emcitate in RTH-beta





EGETIS THERAPEUTICS

Thank you!

Egetis Therapeutics
egetis.com